Aventis Cites Plavix Patent Litigation In Countering Sanofi’s Takeover Bid
Executive Summary
Apotex and Dr. Reddy's have raised a "substantial challenge" to the validity of Sanofi-Synthelabo's compound patent for Plavix, Aventis says in a Securities & Exchange Commission filing
You may also be interested in...
Sanofi Wins Aventis With $8 Bil. In Cash And Nominal Joint Control
Sanofi's winning bid for Aventis includes an additional $8 bil. in cash, nominal joint control of the merged company, and an acknowledgment of Aventis' Franco-German heritage
Sanofi Wins Aventis With $8 Bil. In Cash And Nominal Joint Control
Sanofi's winning bid for Aventis includes an additional $8 bil. in cash, nominal joint control of the merged company, and an acknowledgment of Aventis' Franco-German heritage
Novartis And Aventis Begin Merger Talks; Sanofi Considers Raising Bid
Sanofi will continue to evaluate the market response to its tender offer for Aventis before deciding whether to sweeten its bid, CFO Marie-Helene Laimay said during a first quarter investor call April 22